We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
AstraZeneca shares hit record after Farxiga study
Health Health Headlines News
--AstraZeneca's phase 3 DAPA-HF clinical trial of Farxiga yielded positive results --The data supports an expanded label for Farxiga for both patients with and without diabetes --Financial analysts praised the trial results Shares of AstraZeneca PLC (AZN.LN) reached an all-time high Monday after a clinical study of its drug Farxiga, originally designed to treat diabetes, showed the medicine helped patients who had suffered from heart failure.